Ignite Creation Date:
2025-12-26 @ 4:03 PM
Ignite Modification Date:
2025-12-30 @ 5:29 AM
Study NCT ID:
NCT05007106
Status:
COMPLETED
Last Update Posted:
2025-08-14
First Post:
2021-08-10
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002583', 'term': 'Uterine Cervical Neoplasms'}, {'id': 'D016889', 'term': 'Endometrial Neoplasms'}, {'id': 'D000077195', 'term': 'Squamous Cell Carcinoma of Head and Neck'}, {'id': 'D005706', 'term': 'Gallbladder Neoplasms'}, {'id': 'D018281', 'term': 'Cholangiocarcinoma'}, {'id': 'D004938', 'term': 'Esophageal Neoplasms'}, {'id': 'D064726', 'term': 'Triple Negative Breast Neoplasms'}, {'id': 'D006528', 'term': 'Carcinoma, Hepatocellular'}, {'id': 'D001749', 'term': 'Urinary Bladder Neoplasms'}, {'id': 'D010051', 'term': 'Ovarian Neoplasms'}, {'id': 'D013274', 'term': 'Stomach Neoplasms'}, {'id': 'C565324', 'term': 'Parkinson Disease 4, Autosomal Dominant Lewy Body'}], 'ancestors': [{'id': 'D014594', 'term': 'Uterine Neoplasms'}, {'id': 'D005833', 'term': 'Genital Neoplasms, Female'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D002577', 'term': 'Uterine Cervical Diseases'}, {'id': 'D014591', 'term': 'Uterine Diseases'}, {'id': 'D005831', 'term': 'Genital Diseases, Female'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D002294', 'term': 'Carcinoma, Squamous Cell'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D006258', 'term': 'Head and Neck Neoplasms'}, {'id': 'D001661', 'term': 'Biliary Tract Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D001660', 'term': 'Biliary Tract Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005705', 'term': 'Gallbladder Diseases'}, {'id': 'D000230', 'term': 'Adenocarcinoma'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004935', 'term': 'Esophageal Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D001943', 'term': 'Breast Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D008113', 'term': 'Liver Neoplasms'}, {'id': 'D008107', 'term': 'Liver Diseases'}, {'id': 'D014571', 'term': 'Urologic Neoplasms'}, {'id': 'D001745', 'term': 'Urinary Bladder Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D004701', 'term': 'Endocrine Gland Neoplasms'}, {'id': 'D010049', 'term': 'Ovarian Diseases'}, {'id': 'D000291', 'term': 'Adnexal Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D006058', 'term': 'Gonadal Disorders'}, {'id': 'D013272', 'term': 'Stomach Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C582435', 'term': 'pembrolizumab'}, {'id': 'C531958', 'term': 'lenvatinib'}, {'id': 'D005472', 'term': 'Fluorouracil'}, {'id': 'D002945', 'term': 'Cisplatin'}, {'id': 'D017239', 'term': 'Paclitaxel'}, {'id': 'D000068196', 'term': 'Albumin-Bound Paclitaxel'}, {'id': 'D000093542', 'term': 'Gemcitabine'}, {'id': 'D016190', 'term': 'Carboplatin'}, {'id': 'D000077143', 'term': 'Docetaxel'}, {'id': 'D000068258', 'term': 'Bevacizumab'}, {'id': 'D000069287', 'term': 'Capecitabine'}, {'id': 'D000077150', 'term': 'Oxaliplatin'}], 'ancestors': [{'id': 'D014498', 'term': 'Uracil'}, {'id': 'D011744', 'term': 'Pyrimidinones'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D017606', 'term': 'Chlorine Compounds'}, {'id': 'D007287', 'term': 'Inorganic Chemicals'}, {'id': 'D017672', 'term': 'Nitrogen Compounds'}, {'id': 'D017671', 'term': 'Platinum Compounds'}, {'id': 'D043823', 'term': 'Taxoids'}, {'id': 'D043822', 'term': 'Cyclodecanes'}, {'id': 'D003516', 'term': 'Cycloparaffins'}, {'id': 'D006840', 'term': 'Hydrocarbons, Alicyclic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D004224', 'term': 'Diterpenes'}, {'id': 'D013729', 'term': 'Terpenes'}, {'id': 'D000418', 'term': 'Albumins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D003841', 'term': 'Deoxycytidine'}, {'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D056831', 'term': 'Coordination Complexes'}, {'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}, {'id': 'D003853', 'term': 'Deoxyribonucleosides'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Participants with locally recurrent unresectable or metastatic cervical cancer whose tumors express programmed cell death 1 ligand 1 (PD-LI) and have a combined positive score (CPS) ≥1 will be randomly assigned to treatment with either pembrolizumab/vibostolimab co-formulation or pembrolizumab only. The other study intervention arms will be assigned to participants depending on the selected cancer type.'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 613}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-09-16', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-08', 'completionDateStruct': {'date': '2025-08-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-08-12', 'studyFirstSubmitDate': '2021-08-10', 'studyFirstSubmitQcDate': '2021-08-10', 'lastUpdatePostDateStruct': {'date': '2025-08-14', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-08-16', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-08-05', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)', 'timeFrame': 'Up to approximately 2 years', 'description': 'ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 will be presented.'}, {'measure': 'Progression-Free Survival (PFS) per RECIST 1.1 as Assessed by BICR', 'timeFrame': 'Up to approximately 2 years', 'description': 'PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.'}, {'measure': 'ORR per RECIST 1.1 as Assessed by Investigator in Participants with Selected Solid Tumors', 'timeFrame': 'Up to approximately 2 years', 'description': 'ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by investigator based on RECIST 1.1 will be presented.'}, {'measure': 'PFS per RECIST 1.1 as Assessed by Investigator at 9 months', 'timeFrame': '9 months', 'description': 'PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD.'}, {'measure': 'PFS per RECIST 1.1 as Assessed by Investigator at 12 months', 'timeFrame': '12 months', 'description': 'PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD.'}], 'secondaryOutcomes': [{'measure': 'Overall Survival (OS)', 'timeFrame': 'Up to approximately 5.5 years', 'description': 'OS is defined as the time from randomization to death due to any cause.'}, {'measure': 'PFS per RECIST 1.1 as Assessed by Investigator', 'timeFrame': 'Up to approximately 2 years', 'description': 'PFS is defined as the time from first dose of study treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by investigator will be presented.'}, {'measure': 'Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR', 'timeFrame': 'Up to approximately 2 years', 'description': 'For participants who demonstrate a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until PD or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by BICR will be presented.'}, {'measure': 'DOR per RECIST 1.1 as Assessed by Investigator', 'timeFrame': 'Up to approximately 2 years', 'description': 'For participants who demonstrate a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until PD or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by investigator will be presented.'}, {'measure': 'ORR per RECIST 1.1 as Assessed by Investigator', 'timeFrame': 'Up to approximately 2 years', 'description': 'ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by investigator based on RECIST 1.1 will be presented.'}, {'measure': 'PFS per RECIST 1.1 as Assessed by Investigator in Participants with Cervical Cancer', 'timeFrame': 'Up to approximately 2 years', 'description': 'PFS is defined as the time from first dose of study treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by investigator will be presented.'}, {'measure': 'Change from Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30)', 'timeFrame': 'Baseline and up to approximately 2 years', 'description': 'The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented.'}, {'measure': 'Change from Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5)', 'timeFrame': 'Baseline and up to approximately 2 years', 'description': 'The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score will be presented.'}, {'measure': 'Number of Participants Who Experienced One or More Adverse Events (AEs)', 'timeFrame': 'Up to approximately 2 years', 'description': 'An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.'}, {'measure': 'Number of Participants Who Discontinued Study Intervention Due to an AE', 'timeFrame': 'Up to approximately 2 years', 'description': 'An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Programmed Cell Death-1 (PD1, PD-1)', 'Programmed Death-Ligand 1 (PDL1, PD-L1)'], 'conditions': ['Uterine Cervical Neoplasms', 'Endometrial Neoplasms', 'Squamous Cell Carcinoma of Head and Neck', 'Gallbladder Neoplasms', 'Cholangiocarcinoma', 'Esophageal Neoplasms', 'Triple Negative Breast Neoplasms', 'Hepatocellular Carcinoma', 'Urinary Bladder Neoplasms', 'Ovarian Neoplasms', 'Stomach Neoplasms']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://www.merckclinicaltrials.com/', 'label': 'Merck Clinical Trials Information'}, {'url': 'https://msd.trialsummaries.com/Study/StudyDetails?id=26136&tenant=MT_MSD_9011', 'label': 'Plain Language Summary'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* One of the following histologically or cytologically confirmed, advanced (unresectable or metastatic) solid tumors:\n\n * Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix\n * Endometrial cancer\n * Head and neck squamous cell carcinoma (HNSCC)\n * Unresectable biliary adenocarcinoma (gallbladder or biliary tree \\[intrahepatic or extrahepatic\\] cholangiocarcinoma)\n * Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction (GEJ).\n * Triple-negative breast cancer (TNBC)\n * Hepatocellular carcinoma (HCC)\n * Urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra\n * Ovarian cancer\n * Gastric cancer\n* Measurable disease per RECIST v1.1 as assessed by BICR or local site investigator.\n* Adequately controlled blood pressure (BP) with or without antihypertensive medications.\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).\n* Male participants must agree to follow contraceptive guidance.\n* Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance.\n* Adequate organ function.\n\nExclusion Criteria:\n\n* History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.\n* Prior therapy with anti-programmed cell-death (PD-1), anti-PD-L1, anti-PD-L2, or anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) agent.\n* Prior systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation.\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study medication.\n* Active autoimmune disease that has required systemic treatment in past 2 years.\n* Active infection requiring systemic therapy.\n* Concurrent active hepatitis B and hepatitis C virus infection.\n* History of allogenic tissue/solid organ transplant.\n* Previous treatment with lenvatinib (for participants who will receive lenvatinib in their assigned treatment arm).\n* Has clinically significant cardiovascular disease within 12 months from first dose of study intervention.'}, 'identificationModule': {'nctId': 'NCT05007106', 'briefTitle': 'MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Merck Sharp & Dohme LLC'}, 'officialTitle': 'A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) With Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors', 'orgStudyIdInfo': {'id': '7684A-005'}, 'secondaryIdInfos': [{'id': 'MK-7684A-005', 'type': 'OTHER', 'domain': 'MSD'}, {'id': 'jRCT2031210335', 'type': 'REGISTRY', 'domain': 'jRCT'}, {'id': 'KEYVIBE-005', 'type': 'OTHER', 'domain': 'MSD'}, {'id': '2023-505284-36-00', 'type': 'REGISTRY', 'domain': 'EU CT'}, {'id': 'U1111-1291-4290', 'type': 'REGISTRY', 'domain': 'UTN'}, {'id': '2021-001009-56', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Pembrolizumab/Vibostolimab Co-Formulation', 'description': 'Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion every 3 weeks (Q3W) up to 35 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy.', 'interventionNames': ['Biological: Pembrolizumab/Vibostolimab Co-Formulation', 'Biological: Pembrolizumab']}, {'type': 'EXPERIMENTAL', 'label': 'Pembrolizumab', 'description': 'Participants receive pembrolizumab 200 mg via IV infusion Q3W up to 35 cycles.', 'interventionNames': ['Biological: Pembrolizumab']}, {'type': 'EXPERIMENTAL', 'label': 'Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)', 'description': 'Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 20 mg once daily (qd) up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib.', 'interventionNames': ['Biological: Pembrolizumab/Vibostolimab Co-Formulation', 'Biological: Pembrolizumab', 'Drug: Lenvatinib']}, {'type': 'EXPERIMENTAL', 'label': 'Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)', 'description': 'Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 12 mg (body weight \\[BW\\] ≥60 kg) or lenvatinib 8 mg (BW \\<60 kg) qd up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib.', 'interventionNames': ['Biological: Pembrolizumab/Vibostolimab Co-Formulation', 'Biological: Pembrolizumab', 'Drug: Lenvatinib']}, {'type': 'EXPERIMENTAL', 'label': 'Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin', 'description': 'Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W, plus 5-fluorouracil (5-FU), plus Cisplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with 5-Fluorouracil + Cisplatin.', 'interventionNames': ['Biological: Pembrolizumab/Vibostolimab Co-Formulation', 'Biological: Pembrolizumab', 'Drug: 5-Fluorouracil', 'Drug: Cisplatin']}, {'type': 'EXPERIMENTAL', 'label': 'Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel', 'description': 'Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus paclitaxel as background therapy until meeting discontinuation criteria. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Paclitaxel.', 'interventionNames': ['Biological: Pembrolizumab/Vibostolimab Co-Formulation', 'Biological: Pembrolizumab', 'Drug: Paclitaxel']}, {'type': 'EXPERIMENTAL', 'label': 'Pembrolizumab/Vibostolimab Co-Formulation + Gemcitabine/Cisplatin', 'description': 'Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus gemcitabine (until disease progression or unacceptable toxicity) and cisplatin (up to 8 cycles) as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Gemcitabine/Cisplatin', 'interventionNames': ['Biological: Pembrolizumab', 'Drug: Cisplatin', 'Drug: Gemcitabine']}, {'type': 'EXPERIMENTAL', 'label': 'Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab', 'description': 'Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus carboplatin, paclitaxel, and bevacizumab as local standard of care (SOC) background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Carboplatin/Paclitaxel/Bevacizumab.', 'interventionNames': ['Biological: Pembrolizumab', 'Drug: Paclitaxel', 'Drug: Carboplatin', 'Drug: Docetaxel', 'Drug: Bevacizumab']}, {'type': 'EXPERIMENTAL', 'label': 'Pembrolizumab/Vibostolimab Co-Formulation + Capecitabine/Oxaliplatin', 'description': 'Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus capecitabine and oxaliplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Capecitabine/Oxaliplatin.', 'interventionNames': ['Biological: Pembrolizumab', 'Drug: Capecitabine', 'Drug: Oxaliplatin']}], 'interventions': [{'name': 'Pembrolizumab/Vibostolimab Co-Formulation', 'type': 'BIOLOGICAL', 'otherNames': ['MK-7684A'], 'description': 'Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W', 'armGroupLabels': ['Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin', 'Pembrolizumab/Vibostolimab Co-Formulation', 'Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)', 'Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)', 'Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel']}, {'name': 'Pembrolizumab', 'type': 'BIOLOGICAL', 'otherNames': ['MK-3475', 'KEYTRUDA®'], 'description': 'Pembrolizumab 200 mg administered via IV infusion Q3W.', 'armGroupLabels': ['Pembrolizumab', 'Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin', 'Pembrolizumab/Vibostolimab Co-Formulation', 'Pembrolizumab/Vibostolimab Co-Formulation + Capecitabine/Oxaliplatin', 'Pembrolizumab/Vibostolimab Co-Formulation + Gemcitabine/Cisplatin', 'Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)', 'Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)', 'Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel', 'Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab']}, {'name': 'Lenvatinib', 'type': 'DRUG', 'otherNames': ['Lenvima', 'E7080', 'MK-7902'], 'description': 'Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD', 'armGroupLabels': ['Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)', 'Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)']}, {'name': '5-Fluorouracil', 'type': 'DRUG', 'otherNames': ['5-FU', 'Fluracil'], 'description': '5-FU 800 mg/m\\^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles', 'armGroupLabels': ['Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin']}, {'name': 'Cisplatin', 'type': 'DRUG', 'otherNames': ['Platinol', 'cis Platinum'], 'description': 'Cisplatin administered via IV infusion', 'armGroupLabels': ['Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin', 'Pembrolizumab/Vibostolimab Co-Formulation + Gemcitabine/Cisplatin']}, {'name': 'Paclitaxel', 'type': 'DRUG', 'otherNames': ['Taxol', 'Abraxane', 'Anzatax'], 'description': "Paclitaxel administered via IV infusion at investigator's choice of dose", 'armGroupLabels': ['Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel', 'Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab']}, {'name': 'Gemcitabine', 'type': 'DRUG', 'description': 'Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity', 'armGroupLabels': ['Pembrolizumab/Vibostolimab Co-Formulation + Gemcitabine/Cisplatin']}, {'name': 'Carboplatin', 'type': 'DRUG', 'description': "Carboplatin administered via IV infusion at investigator's choice of dose and frequency", 'armGroupLabels': ['Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab']}, {'name': 'Docetaxel', 'type': 'DRUG', 'description': 'For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles', 'armGroupLabels': ['Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab']}, {'name': 'Bevacizumab', 'type': 'DRUG', 'description': 'Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles', 'armGroupLabels': ['Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab']}, {'name': 'Capecitabine', 'type': 'DRUG', 'description': 'Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles', 'armGroupLabels': ['Pembrolizumab/Vibostolimab Co-Formulation + Capecitabine/Oxaliplatin']}, {'name': 'Oxaliplatin', 'type': 'DRUG', 'description': 'Oxaliplatin administered via IV infusion Q3W up to 35 cycles', 'armGroupLabels': ['Pembrolizumab/Vibostolimab Co-Formulation + Capecitabine/Oxaliplatin']}]}, 'contactsLocationsModule': {'locations': [{'zip': '99508', 'city': 'Anchorage', 'state': 'Alaska', 'country': 'United States', 'facility': 'Alaska Womens Cancer Care ( Site 1016)', 'geoPoint': {'lat': 61.21806, 'lon': -149.90028}}, {'zip': '91010', 'city': 'Duarte', 'state': 'California', 'country': 'United States', 'facility': 'City of Hope Comprehensive Cancer Center ( Site 1001)', 'geoPoint': {'lat': 34.13945, 'lon': -117.97729}}, {'zip': '92868-3201', 'city': 'Orange', 'state': 'California', 'country': 'United States', 'facility': 'University of California, Irvine (UCI) Health - UC Irvine Me-Chao Family Comprehensive Cancer Cente', 'geoPoint': {'lat': 33.78779, 'lon': -117.85311}}, {'zip': '48201', 'city': 'Detroit', 'state': 'Michigan', 'country': 'United States', 'facility': 'Karmanos Cancer Institute ( Site 1007)', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '07920', 'city': 'Basking Ridge', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Memorial Sloan Kettering - Basking Ridge ( Site 1023)', 'geoPoint': {'lat': 40.70621, 'lon': -74.54932}}, {'zip': '07748', 'city': 'Middletown', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Memorial Sloan Kettering - Monmouth ( Site 1022)', 'geoPoint': {'lat': 40.39428, 'lon': -74.11709}}, {'zip': '07645', 'city': 'Montvale', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Memorial Sloan Kettering - Bergen ( Site 1025)', 'geoPoint': {'lat': 41.04676, 'lon': -74.02292}}, {'zip': '11725', 'city': 'Commack', 'state': 'New York', 'country': 'United States', 'facility': 'Memorial Sloan Kettering- Commack ( Site 1021)', 'geoPoint': {'lat': 40.84288, 'lon': -73.29289}}, {'zip': '10604', 'city': 'Harrison', 'state': 'New York', 'country': 'United States', 'facility': 'Memorial Sloan Kettering - Westchester ( Site 1020)', 'geoPoint': {'lat': 40.96899, 'lon': -73.71263}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Memorial Sloan Kettering Cancer Center ( Site 1002)', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '11553', 'city': 'Uniondale', 'state': 'New York', 'country': 'United States', 'facility': 'Memorial Sloan Kettering - Nassau ( Site 1026)', 'geoPoint': {'lat': 40.70038, 'lon': -73.59291}}, {'zip': '74146', 'city': 'Tulsa', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1024)', 'geoPoint': {'lat': 36.15398, 'lon': -95.99277}}, {'zip': '57104', 'city': 'Sioux Falls', 'state': 'South Dakota', 'country': 'United States', 'facility': 'Sanford Cancer Center-Gynecologic Oncology ( Site 1015)', 'geoPoint': {'lat': 43.54369, 'lon': -96.72796}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Houston Methodist Hospital ( Site 1017)', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': 'K7L 2V7', 'city': 'Kingston', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1051)', 'geoPoint': {'lat': 44.22976, 'lon': -76.48098}}, {'zip': 'M5G 2M9', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Princess Margaret Cancer Centre ( Site 1056)', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': '7500921', 'city': 'Santiago', 'state': 'Region M. de Santiago', 'country': 'Chile', 'facility': 'FALP-UIDO ( Site 1401)', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '7510032', 'city': 'Santiago', 'state': 'Region M. de Santiago', 'country': 'Chile', 'facility': 'Oncovida ( Site 1405)', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '8420383', 'city': 'Santiago', 'state': 'Region M. de Santiago', 'country': 'Chile', 'facility': 'Bradfordhill-Clinical Area ( Site 1402)', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '4800827', 'city': 'Temuco', 'state': 'Región de la Araucanía', 'country': 'Chile', 'facility': 'James Lind Centro de Investigacion del Cancer ( Site 1404)', 'geoPoint': {'lat': -38.73628, 'lon': -72.59738}}, {'zip': '050030', 'city': 'Medellín', 'state': 'Antioquia', 'country': 'Colombia', 'facility': 'Fundacion Colombiana de Cancerología Clinica Vida ( Site 1422)', 'geoPoint': {'lat': 6.245, 'lon': -75.57151}}, {'zip': '080020', 'city': 'Barranquilla', 'state': 'Atlántico', 'country': 'Colombia', 'facility': 'Clinica de la Costa S.A.S. ( Site 1421)', 'geoPoint': {'lat': 10.96854, 'lon': -74.78132}}, {'zip': '111511', 'city': 'Bogotá', 'state': 'Cundinamarca', 'country': 'Colombia', 'facility': 'Instituto Nacional de Cancerología-Clinical Oncology ( Site 1425)'}, {'zip': '661001', 'city': 'Pereira', 'state': 'Risaralda Department', 'country': 'Colombia', 'facility': 'Oncologos del Occidente ( Site 1424)', 'geoPoint': {'lat': 4.81428, 'lon': -75.69488}}, {'zip': '681017', 'city': 'Piedecuesta', 'state': 'Santander Department', 'country': 'Colombia', 'facility': 'Fundación Cardiovascular de Colombia ( Site 1423)', 'geoPoint': {'lat': 6.98789, 'lon': -73.04953}}, {'zip': '69373 Cedex 08', 'city': 'Lyon', 'state': 'Auvergne-Rhône-Alpes', 'country': 'France', 'facility': 'CENTRE LEON BERARD-Medical oncology ( Site 1151)', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '21079', 'city': 'Dijon', 'state': 'Cote-d Or', 'country': 'France', 'facility': 'Centre Georges François Leclerc ( Site 1155)', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}, {'zip': '34298', 'city': 'Montpellier', 'state': 'Herault', 'country': 'France', 'facility': 'Institut Regional du Cancer Montpellier ( Site 1157)', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'zip': '94800', 'city': 'Villejuif', 'state': 'Paris', 'country': 'France', 'facility': 'Gustave Roussy-medicine departement ( Site 1153)', 'geoPoint': {'lat': 48.7939, 'lon': 2.35992}}, {'zip': '84000', 'city': 'Avignon', 'state': 'Vaucluse', 'country': 'France', 'facility': 'Sainte Catherine Institut du Cancer Avignon Provence-Oncologie médicale ( Site 1156)', 'geoPoint': {'lat': 43.94834, 'lon': 4.80892}}, {'zip': '75248', 'city': 'Paris', 'country': 'France', 'facility': 'Institut Curie ( Site 1152)', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '69120', 'city': 'Heidelberg', 'state': 'Baden-Wurttemberg', 'country': 'Germany', 'facility': 'Universitaetsklinikum Heidelberg-Nationales Centrum für Tumorerkrankungen ( Site 1180)', 'geoPoint': {'lat': 49.40768, 'lon': 8.69079}}, {'zip': '72076', 'city': 'Tübingen', 'state': 'Baden-Wurttemberg', 'country': 'Germany', 'facility': 'Universitaetsklinikum Tuebingen-Department of Internal Medicine VIII - Medical Oncology, ECTU, Pne', 'geoPoint': {'lat': 48.52266, 'lon': 9.05222}}, {'zip': '81337', 'city': 'München', 'state': 'Bavaria', 'country': 'Germany', 'facility': 'Klinikum der Universität München Großhadern ( Site 1176)', 'geoPoint': {'lat': 48.69668, 'lon': 13.46314}}, {'zip': '40225', 'city': 'Düsseldorf', 'state': 'North Rhine-Westphalia', 'country': 'Germany', 'facility': 'Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 1172)', 'geoPoint': {'lat': 51.22172, 'lon': 6.77616}}, {'zip': '12203', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 1171)', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '3109601', 'city': 'Haifa', 'country': 'Israel', 'facility': 'Rambam Health Care Campus-Oncology ( Site 1141)', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'zip': '9112001', 'city': 'Jerusalem', 'country': 'Israel', 'facility': 'Hadassah Medical Center-Oncology ( Site 1142)', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'zip': '5265601', 'city': 'Ramat Gan', 'country': 'Israel', 'facility': 'Sheba Medical Center-ONCOLOGY ( Site 1144)', 'geoPoint': {'lat': 32.08227, 'lon': 34.81065}}, {'zip': '6423906', 'city': 'Tel Aviv', 'country': 'Israel', 'facility': 'Sourasky Medical Center-Oncology ( Site 1143)', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'zip': '00168', 'city': 'Rome', 'state': 'Lazio', 'country': 'Italy', 'facility': 'Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 1136)', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': '20132', 'city': 'Milan', 'state': 'Lombardy', 'country': 'Italy', 'facility': 'Ospedale San Raffaele-Oncologia Medica ( Site 1135)', 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}}, {'zip': '20089', 'city': 'Rozzano', 'state': 'Milano', 'country': 'Italy', 'facility': 'Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1138)', 'geoPoint': {'lat': 45.38193, 'lon': 9.1559}}, {'zip': '20141', 'city': 'Milan', 'country': 'Italy', 'facility': 'Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '80131', 'city': 'Napoli', 'country': 'Italy', 'facility': 'Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1134)', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'zip': '464-8681', 'city': 'Nagoya', 'state': 'Aichi-ken', 'country': 'Japan', 'facility': 'Aichi Cancer Center Hospital ( Site 1324)', 'geoPoint': {'lat': 35.18147, 'lon': 136.90641}}, {'zip': '277-8577', 'city': 'Kashiwa', 'state': 'Chiba', 'country': 'Japan', 'facility': 'National Cancer Center Hospital East ( Site 1321)', 'geoPoint': {'lat': 35.86224, 'lon': 139.97732}}, {'zip': '541-8567', 'city': 'Osaka', 'country': 'Japan', 'facility': 'Osaka International Cancer Institute ( Site 1323)', 'geoPoint': {'lat': 34.69379, 'lon': 135.50107}}, {'zip': '104-0045', 'city': 'Tokyo', 'country': 'Japan', 'facility': 'National Cancer Center Hospital ( Site 1322)', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'zip': '1066CX', 'city': 'Amsterdam', 'state': 'North Holland', 'country': 'Netherlands', 'facility': 'Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1121)', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'zip': '3015 GD', 'city': 'Rotterdam', 'state': 'South Holland', 'country': 'Netherlands', 'facility': 'Erasmus Medisch Centrum-Medical Oncology ( Site 1122)', 'geoPoint': {'lat': 51.9225, 'lon': 4.47917}}, {'zip': '02-781', 'city': 'Warsaw', 'state': 'Masovian Voivodeship', 'country': 'Poland', 'facility': 'Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 1101', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '80-952', 'city': 'Gdansk', 'state': 'Pomeranian Voivodeship', 'country': 'Poland', 'facility': 'Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 1103)', 'geoPoint': {'lat': 54.35227, 'lon': 18.64912}}, {'zip': '75-581', 'city': 'Koszalin', 'state': 'West Pomeranian Voivodeship', 'country': 'Poland', 'facility': 'Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1104)', 'geoPoint': {'lat': 54.19438, 'lon': 16.17222}}, {'zip': '03080', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Seoul National University Hospital-Internal Medicine ( Site 1312)', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '03722', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1311)', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '05505', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Asan Medical Center ( Site 1313)', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '08907', 'city': 'Hospitalet', 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1113)'}, {'zip': '28223', 'city': 'Pozuelo de Alarcón', 'state': 'Madrid', 'country': 'Spain', 'facility': 'HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1117)', 'geoPoint': {'lat': 40.43293, 'lon': -3.81338}}, {'zip': '28034', 'city': 'Madrid', 'state': 'Madrid, Comunidad de', 'country': 'Spain', 'facility': 'Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1111)', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28027', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Clinica Universidad de Navarra-Medical Oncology ( Site 1118)', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '41013', 'city': 'Seville', 'country': 'Spain', 'facility': 'HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 1114)', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '704', 'city': 'Tainan', 'country': 'Taiwan', 'facility': 'NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 1302)', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'zip': '10002', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'National Taiwan University Hospital-Oncology ( Site 1301)', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '10449', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Mackay Memorial Hospital ( Site 1305)', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '333', 'city': 'Taoyuan District', 'country': 'Taiwan', 'facility': 'Chang Gung Medical Foundation-Linkou Branch ( Site 1304)', 'geoPoint': {'lat': 24.9896, 'lon': 121.3187}}, {'zip': '34098', 'city': 'Istanbul- Fatih', 'state': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Istanbul Universitesi Cerrahpasa ( Site 1203)'}, {'zip': '01250', 'city': 'Adana', 'country': 'Turkey (Türkiye)', 'facility': 'Baskent University Dr. Turgut Noyan Research and Training Center ( Site 1201)', 'geoPoint': {'lat': 36.98615, 'lon': 35.32531}}, {'zip': '06230', 'city': 'Ankara', 'country': 'Turkey (Türkiye)', 'facility': 'Hacettepe Universitesi-oncology hospital ( Site 1209)', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'zip': '06800', 'city': 'Ankara', 'country': 'Turkey (Türkiye)', 'facility': 'Ankara City Hospital-Medical Oncology ( Site 1202)', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'zip': '22030', 'city': 'Edirne', 'country': 'Turkey (Türkiye)', 'facility': 'Trakya University-Medical Oncology ( Site 1207)', 'geoPoint': {'lat': 41.67719, 'lon': 26.55597}}, {'zip': '34303', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Acibadem Universitesi Atakent Hastanesi ( Site 1208)', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '34722', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1204)', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}], 'overallOfficials': [{'name': 'Medical Director', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Merck Sharp & Dohme LLC'}]}, 'ipdSharingStatementModule': {'url': 'https://externaldatasharing-msd.com/', 'ipdSharing': 'YES', 'description': 'https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Merck Sharp & Dohme LLC', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}